Drug-Device Combination Products Market

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• DRUG-DEVICE COMBINATION PRODUCTS MARKET ANALYSIS
• Drug-Device Combination Products Market, By
  Product Type (Drug Eluting Stents (Coronary
  stent, Peripheral Vascular stents), Infusion
  pumps (Implantable, Ambulatory),
  Photosensitizers, Orthopedic combination products
  (Bone graft imlants antibiotic loaded bone
  cements), Wound care combination products,
  Inhalers (Nebulizers, MDI, DPI), Transdermal
  patches, Others( Intraocular implants, drug
  eluting beads)), and By Region (North America,
  Latin America, Europe, Asia Pacific, Middle East
  Africa) - Size, Share, Outlook, and Opportunity
  Analysis, 2020 - 2027

3

• Global Drug-Device Combination Products Market
  Drivers
• Increasing prevalence of chronic disorders is
  expected to propel growth of the global
  drug-device combination products market over the
  forecast period. For instance, according to the
  study, Global and regional diabetes prevalence
  estimates for 2019 and projections for 2030 and
  2045 Results from the International Diabetes
  Federation Diabetes Atlas, 9th edition,
  published in the journal Diabetes Research and
  Clinical Practice, in September 2019, 463 million
  people are expected to suffer from diabetes in
  2019 worldwide and the number is expected to
  reach 578 million by 2030 and 700 million by
  2045.
• Moreover, increasing geriatric population is also
  expected to aid in growth of the market. For
  instance, according to the U.S. Census Bureau,
  the U.S. geriatric population is expected to
  reach 77 million by 2034.
• North America held dominant position in the
  global drug-device combination products market in
  2019, accounting for 41.4 share in terms of
  value, followed by Europe and Asia Pacific,
  respectively

4

• Figure 1. Global Drug-Device Combination Products
  Market Share (), by Value, by Region, 2019

5

• Global Drug-Device Combination Products Market
  Restraints
• Drug-device combination products increase the
  risk of infections, which is expected to hinder
  growth of the market. Although stent infection is
  rare, it is associated with high morbidity and
  mortality. Drug eluting stents (DES) are
  associated with higher infection risk than bare
  metal stent (BMS), owing to their
  antiproliferative effects.
• Moreover, presence of stringent and non-specific
  regulatory pathway for approval of Drug-device
  combination products is also expected to limit
  the market growth. There are separate regulatory
  approval pathways for pharmaceutical products and
  medical devices in the U.S. Investigational new
  drug (IND) application process is suited for
  pharmaceutical products, whereas medical devices
  fall under the investigational device exemption
  (IDE) pathway.

6
Drug-Device Combination Products Market Report
Coverage

7
Global Drug-Device Combination Products Market
Opportunities

• Adoption of cloud-based data management software
  in combination products is expected to offer
  lucrative growth opportunities for players in the
  global drug-device combination products market.
  For instance, in January 2020, Medtronic plc
  launched Efficio, a cloud-based data management
  software for use with the SynchroMed II
  intrathecal drug delivery system, for effective
  management of targeted drug delivery pump.
• Moreover, launch of generic combination products
  is also expected to aid in growth of the market.
  For instance, August 2019, Teva Pharmaceutical
  Industries Ltd. launched generic version of
  Mylans EpiPen for young children.
• The global drug-device combination products
  market was valued at US 115.0 Bn in 2019 and is
  forecast to reach a value of US 214.1 Bn by 2027
  at a CAGR of 8.1 between 2020 and 2027.

8
Figure 2. Global Drug-Device Combination Products
Market Value (US Bn), and Y-o-Y Growth (),
2019-2027

9

• Market Trends/Key Takeaways
• Major players in the market are focused on
  approval and launch of new products to expand
  their product portfolio. For instance, in October
  2019, Becton, Dickinson and Company launched the
  BD Intevia 1mL two-step disposable auto-injector.
• The market is witnessing higher preference for
  nasal sprays over auto injectors. For instance,
  in October 2019, Bryn Pharma, LLC
  reported that patients prefer bi-dose epinephrine
  nasal spray over Epipen auto injector. The
  company presented the related data at the
  American Academy of Pediatrics (AAP) National
  Conference Exhibition.

10

• Global Drug-Device Combination Products Market
  Competitive Landscape
• Major players operating in the global drug-device
  combination products market include, Teva
  Pharmaceutical Industries Ltd., Becton, Dickinson
  and Company, Integer Holdings Corporation, Abbott
  Laboratories, Medtronic plc, Allergan, Inc.,
  Alcon, Inc., Arrow International, Inc., Bausch
  Lomb, Inc., Boston Scientific Corporation, ALK,
  SINOMED, Kaléo, Haselmeier, Flowonix Medical,
  Inc., CareFusion Corporation, and Covidien PLC.

11

• Global Drug-Device Combination Products Market
  Key Developments
• Major players in the market are focused on
  approval and launch of new products to expand
  their product portfolio. For instance, in
  February 2020, Flowonix Medical, Inc. received
  the U.S. Food and Drug Administration approval
  for its Prometra II Programmable Pump System for
  use with intrathecal baclofen. Prometra II Pump
  utilizes a pressure-driven, valve-gated delivery
  mechanism to deliver boluses of medication into
  the intrathecal space.
• Major players in the market are focused on
  adopting partnership strategies to expand their
  product portfolio. For instance, in October 2019,
  Haselmeier, a manufacturer of self-injection
  devices, partnered with Stevanato Group, a
  producer of glass primary packaging based in
  Italy, for development, manufacturing, and supply
  of the axis-D pen-injector in the therapeutic
  area of diabetes care.

12

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/drug-device-combination-products-ma
  rket-3919

13
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

14
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

15
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/